Literature DB >> 36098945

Spatio-temporal clustering of amyotrophic lateral sclerosis in France: A population-based study.

Farid Boumédiene1, Benoît Marin1, Jaime Luna1,2, Vincent Bonneterre3, William Camu4, Emmeline Lagrange5, Gérard Besson5, Florence Esselin4, Elisa De La Cruz4, Géraldine Lautrette2, Pierre Marie Preux1,6, Philippe Couratier7,8.   

Abstract

OBJECTIVE: To assess spatial aggregates of amyotrophic lateral sclerosis (ALS) incident cases, using a solid geo-epidemiological statistical method, in France.
METHODS: This population-based study (2003-2011) investigated 47.1 million person-years of follow-up (PYFU). Case ascertainment of incident ALS cases was based on multiple sources (ALS referral centers, hospital centres and health insurance data). Neurologists confirmed all ALS diagnoses. Exhaustiveness was estimated through capture-recapture. Aggregates were investigated in four steps: (a) geographical modelling (standardized incidence ratio (SIR) calculation), (b) analysis of the spatial distribution of incidence (Phothoff-Winttinghill's test, Global Moran's Index, Kulldorf's spatial scan statistic, Local Moran's Index), (c) classification of the level of certainty of spatial aggregates (i.e. definite cluster; probable over-incidence area; possible over-incidence area) and (d) evaluation of the robustness of the results.
RESULTS: The standardized incidence of ALS was 2.46/100,000 PYFU (95% CI 2.31-2.63, European population as reference) based on 1199 incident cases. We identified 13 areas of spatial aggregates: one cluster (stable in robustness analysis), five probable over-incidence areas (2 stable in robustness analysis) and seven possible over-incidence areas (including 4 stable areas in robustness analysis). A cluster was identified in the Rhône-Alpes region: 100 observed vs 54.07 expected cases for 2,411,514 PYFU, SIR: 1.85 (95% CI 1.50-2.25).
CONCLUSION: We report here one of the largest investigations of incidence and spatial aggregation of ALS ever performed in a western country. Using a solid methodology framework for case ascertainment and cluster analysis, we identified 13 areas that warrant further investigation.
© 2022. Springer Nature B.V.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Cluster analysis; Epidemiology; France; Incidence; Registries

Year:  2022        PMID: 36098945     DOI: 10.1007/s10654-022-00904-2

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   12.434


  30 in total

Review 1.  Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin.

Authors:  Benoît Marin; Giancarlo Logroscino; Farid Boumédiene; Anaïs Labrunie; Philippe Couratier; Marie-Claude Babron; Anne Louise Leutenegger; Pierre Marie Preux; Ettore Beghi
Journal:  Eur J Epidemiol       Date:  2015-10-12       Impact factor: 8.082

Review 2.  The analysis of disease clusters, Part I: State of the art.

Authors:  G M Jacquez; L A Waller; R Grimson; D Wartenberg
Journal:  Infect Control Hosp Epidemiol       Date:  1996-05       Impact factor: 3.254

3.  Epidemiological study of amyotrophic lateral sclerosis and allied disorders in the Kii Peninsula (Japan).

Authors:  S Araki; Y Iwahashi; Y Kuroiwa
Journal:  J Neurol Sci       Date:  1967 Mar-Apr       Impact factor: 3.181

4.  Occurrence of beta-methylamino-l-alanine (BMAA) in ALS/PDC patients from Guam.

Authors:  S J Murch; P A Cox; S A Banack; J C Steele; O W Sacks
Journal:  Acta Neurol Scand       Date:  2004-10       Impact factor: 3.209

Review 5.  State of play in amyotrophic lateral sclerosis genetics.

Authors:  Alan E Renton; Adriano Chiò; Bryan J Traynor
Journal:  Nat Neurosci       Date:  2013-12-26       Impact factor: 24.884

Review 6.  Amyotrophic lateral sclerosis and environmental factors.

Authors:  Virginia Bozzoni; Orietta Pansarasa; Luca Diamanti; Guido Nosari; Cristina Cereda; Mauro Ceroni
Journal:  Funct Neurol       Date:  2016 Jan-Mar

7.  Amyotrophic lateral sclerosis and parkinsonism-dementia complex of Guam: changing incidence rates during the past 60 years.

Authors:  Chris C Plato; Ralph M Garruto; Douglas Galasko; Ulla-Katrina Craig; Meropi Plato; Anthony Gamst; Jose M Torres; Wigbert Wiederholt
Journal:  Am J Epidemiol       Date:  2003-01-15       Impact factor: 4.897

8.  Searching for a link between the L-BMAA neurotoxin and amyotrophic lateral sclerosis: a study protocol of the French BMAALS programme.

Authors:  Aurélie Delzor; Philippe Couratier; Farid Boumédiène; Marie Nicol; Michel Druet-Cabanac; François Paraf; Annick Méjean; Olivier Ploux; Jean-Philippe Leleu; Luc Brient; Marion Lengronne; Valérie Pichon; Audrey Combès; Saïda El Abdellaoui; Vincent Bonneterre; Emmeline Lagrange; Gérard Besson; Dominique J Bicout; Jean Boutonnat; William Camu; Nicolas Pageot; Raul Juntas-Morales; Valérie Rigau; Estelle Masseret; Eric Abadie; Pierre-Marie Preux; Benoît Marin
Journal:  BMJ Open       Date:  2014-09-01       Impact factor: 2.692

9.  Dietary BMAA exposure in an amyotrophic lateral sclerosis cluster from southern France.

Authors:  Estelle Masseret; Sandra Banack; Farid Boumédiène; Eric Abadie; Luc Brient; Fabrice Pernet; Raoul Juntas-Morales; Nicolas Pageot; James Metcalf; Paul Cox; William Camu
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

Review 10.  Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis.

Authors:  Benoît Marin; Farid Boumédiene; Giancarlo Logroscino; Philippe Couratier; Marie-Claude Babron; Anne Louise Leutenegger; Massimilano Copetti; Pierre-Marie Preux; Ettore Beghi
Journal:  Int J Epidemiol       Date:  2017-02-01       Impact factor: 7.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.